A carregar...

New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch

A phase I trial of PF-03084014, an oral reversible γ-secretase inhibitor (GSI), in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but ofte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Hughes, Dennis P.M., Kummar, Shivaani, Lazar, Alexander J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4306586/
https://ncbi.nlm.nih.gov/pubmed/25336699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1660
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!